Toremifene concentration and multidrug resistance in lung tumors

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1996, Pages 212-216

  Liippo, Kari ^a   Ellmén, Juha ^b   Vänttinen, Esko ^a   Anttila, Markku ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Antiestrogen; Lung cancer; Multidrug resistance; Pharmacokinetics study; Toremifene

Indexed keywords

ANTIESTROGEN; DRUG METABOLITE; TOREMIFENE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; FLUORESCENCE; GOOD CLINICAL PRACTICE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LUNG; LUNG CANCER; MALE; MULTIDRUG RESISTANCE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0031060429     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050562     Document Type: Article

References (20)

1. Anttila M, Laakso S, Nyländen P, Sotaniemi EA (1995) Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther 57:628
2. Baker JW, Wiebe UJ, Koester SK, Emshoff UD, Mäenpää JU, Wurz GT, DeGregorio MW (1992) Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells. Breast Cancer 24:43
3. Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olven I, Leben G (1992) Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 30:174
4. Chatterjee M, Harris AL (1990) Enhancement of adriamycin toxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-ADR, by toremifene and its modulation by alfa-1 acid glycoprotein. Eur J Cancer 26:432
5. Dano K (1973) Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466
6. DeGregorio MW, Fono JM, Benz CC, Wiebe V (1989) Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359
7. Endicott JR, Ling V (1989) The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58:136
8. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. Cancer 65:1895
9. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152
10. Kirk J, Houlbrook S, Stuart N, Strandford I, Harris A, Carmichael J (1993) Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites. Eur J Cancer 29A:1152
11. Kirk J, Houlbrook S, Stuart NS, Stratford U, Harris AL, Carmichael J (1993) Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67:1189
12. Mäenpää J, Sipilä P, Kangas L, Karnani P, Grönros M (1992) Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer. Gynecol Oncol 46:292
13. Poupon M, Arvelo F, Goguel A, Bourgeois Y, Jacrot M, Hanania N, Arriagada R, Le Chevalier T (1993) Response of small cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 85:2029
14. Safa AR (1992) Photoaffinity labelling of p-glycoprotein in multi-drug resistant cells. Cancer Invest 10:295
15. Sipilä H, Näntö C, Kangas L (1988) Binding of toremifene to human serum proteins. Pharmacol Toxicol 63:62
16. Slater LM, Sweet P, Stupecky M (1986) Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235
17. Tsuruo T, Iida H, Tsukagoshi S (1982) Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonist and calmodulin inhibitors. Cancer Res 42:4730
18. Wiebe V, Koester S, Lindberg M, Emshoff V, Baker J, Wurz G, DeGregorio M (1992) Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells. Invest New Drugs 10:63
19. Wurz GT, Emshoff VD, DeGregorio MW, Wiebe VJ (1992) Targeting chemosensitizing doses of toremifene based on protein binding. Cancer Chemother Pharmacol 31:412
20. Zamona JM, Pearce HL, Beck WT (1988) Physical-chemical properties shared by compounds that modulate multiple drug resistance in human leukaemia cells. Mol Pharmacol 33:454